8/6/2023 0 Comments Novamind market capNew research provides evidence that MDMA-assisted psychotherapy can improve and extend lives of patients with chronic and severe posttraumatic stress disorder while also reducing healthcare costs. Mind Cure Health announced that a special committee of the company’s board of directors has concluded the initial phases of its previously announced strategic review process. Additional PCT patent applications are expected to publish over the coming months. Importantly, there were no major toxicological findings after twice daily oral administration of BMB-101 throughout the study period.Ĭalifornia activists drop 2022 psilocybin legalization ballot initiative after falling short of signature requirement: “For those of you working on ending the drug war…keep fighting the good fight, it’s worth it.”Ĭolorado activists have made a decision: of the four psychedelics reform ballot initiatives that they drafted and filed for the November ballot, they will proceed with a measure to legalize psilocybin, create licensed “healing centers” where people can use the psychedelic for therapeutic purposes and provide a pathway for record sealing for prior convictions.Įnveric Biosciences announced that the Company’s first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization. Lorenz will lead Awakn’s therapeutics commercialization activities in the United States, starting with the launch of its Licensing Partnership business which is scheduled and expected to generate revenue for the second half of 2022.Īwakn Life Sciences also announced that Awakn Clinics London has received Care Quality Commission’s (CQC) formal approval to begin treatments for addiction and mental health.īright Minds Biosciences announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101. Head of Commercial Development, effective immediately. CompanyĪwakn Life Sciences announced that the company has appointed Kevin Lorenz as their U.S. Novamind and Wesana Health topped the junior gainers. Field Trip has previously signed leases for Field Trip Health Centers in several cities, including Stamford, CT. Of note: Field Trip Health found a bid (+17.8 on Friday +34.28% overall) as Connecticut legislative committee approved a bill that would allow the state up to provide patients with access to psychedelic-assisted treatment with substances like MDMA and psilocybin. Strong performance for several psychedelic stocks, as the global stock market rebound raised all boats, benefitting speculative psychedelic plays. Weekly period technical snapshot, PSYK ETF: OSCILLATORS Here’s how the Health Care (Biotechnology) sector performed: The broad markets had their strongest gains in nearly two years, with NASDAQ 100 ↑8.63% and S&P 500 ↑6.50% rising despite the Federal Reserve raising its benchmark interest rate by 25 basis points. The Horizon Psychedelic Stock Index ETF (PSYK) advanced ↑ 4.71%, but trailed peers indexes such as the Nasdaq Junior Biotechnology Index ( ↑7.25%) and Nasdaq Biotechnology Ishares ETF ( ↑8.57%). The biggest psychedelic stocks mostly rose this past week as volumes generally picked up. Psychedelic Stocks Rise, But Underperform Broad Biopharma Peers Source: 10,000 iterations of a Monte Carlo simulation assuming PTSD progression risk varied from 0.05 to 0.15 annually in a uniform distribution in patients receiving MDMA-Assisted Therapy 1,000 patients over a 30-year analytic horizonģ. MindMed is a clinical-stage biotech company developing the next generation of psychedelic-inspired medicines and therapies. (NASDAQ: MNMD) (NEO:MMED) to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder (GAD) in adults. (CNSX: NM) (OTCMKTS: NVMDF) has been selected by Mind Medicine, Inc. Novamind To Host MindMed Phase IIb Trial For LSD And Anxiety The FDA response also provided important insights pertaining to advancing SANA-013 as a potential treatment for TBI-related MDD.Ĥ. Wesana intends to initiate its in-human clinical study program in late 2022. The company believes the written response provides a path to agreements on IND-enabling studies and validates the team’s effort and accomplishments over the past year. The company received positive written responses from the FDA on March 11 th outlining the requirements to open the IND and commence with clinical studies for SANA-013. Read more: /JLdyYKSDd0- Wesana Health March 14, 2022 BREAKING NEWS: Wesana Pre-IND Meeting Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials in Q4 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |